Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« A Lovely Petite Compound | Main | November Conference on Drug Discovery in Boston »

October 3, 2012

AstraZeneca Stops Buying Its Own Stock

Email This Entry

Posted by Derek

So after all the talking we've done around here about stock buybacks in the pharma world, it's worth noting that the new CEO of AstraZeneca has halted their program. Naturally, that has people talking about what they're going to use the money for otherwise - that is, what company they're going to buy. But it's interesting to see a public mention of the buyback program hitting the brakes like this. . .

Comments (2) + TrackBacks (0) | Category: Business and Markets


COMMENTS

1. Anonymous on October 3, 2012 9:18 PM writes...

After the aquisition, Pascal Soriot became CEO of Genentech, replacing Art Levinson. He didn't last long (WHY???) and moved back to Roche in Basel as COO. Now he's at AZ. What went wrong over at Roche. Any thoughts??

Permalink to Comment

2. Kissthechemist on October 5, 2012 5:58 AM writes...

The sum total of my knowledge of financial markets can be written on a nanotube, but for me, one driving force in the recent decline in big pharma is the instability - the constant changes in direction, often after mergers and aquisitions, and its demoralising and demotivating effects on the workers at the research coal-face, those who keep their jobs, that is.

Pharma is a marathon, not a sprint, but a lot of comapnies won't play it that way (eg the brand new pole of excellence that shuts it's doors permanantly inside 5 years).

The money theme keeps coming up here recently and I'm glad, 'cos there's lots of it around in Pharma being used for things other than turning it into a pipeline. Its clear the way we do research has to evolve but the idea floated the other day by Andrew Lo and friends, for example, is starting to look like its really worth trying.

Just for once, I'd like to see a major company trying something other than stock buy backs and aquisitions to feed the pipeline. Maybe it's time has come?

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
The Smallest Drugs
Life Is Too Short For Some Journal Feeds
A New Look at Phenotypic Screening
Small Molecules - Really, Really Small
InterMune Bought
Citable Garbage
The Palbociclib Saga: Or Why We Need a Lot of Drug Companies
Why Not Bromine?